Vanguard Capital Management
OTLK icon

Vanguard Capital Management’s Outlook Therapeutics OTLK Stock Holding History

Vanguard Capital Management’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.96M Buy
4,376,872
+2,409,712
+122% +$1.49M ﹤0.01% 2991
2026
Q1 		$405K Buy
+1,967,160
New +$850K ﹤0.01% 3709

Other funds holding OTLK

Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
GWM
Gilpin Wealth Management Denver, Colorado $145M AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return

Vanguard Capital Management's OTLK Position: Q2 2026 in Review

Vanguard Capital Management increased its Outlook Therapeutics (OTLK) stake by 122% in Q2 2026, buying an estimated $1.49M and bringing the position to 4,376,872 shares worth $6.96M. The position accounts for ﹤0.01% of the portfolio, ranked #2991.

Vanguard Capital Management first reported a position in OTLK in Q1 2026 and has held it in 2 quarters since. 64 funds tracked by Wall St. Rank hold OTLK as of Q2 2026.

  • Vanguard Capital Management held 4,376,872 shares of Outlook Therapeutics worth $6.96M as of Q2 2026.
  • Vanguard Capital Management bought 2,409,712 Outlook Therapeutics shares in Q2 2026, an estimated $1.49M.
  • Outlook Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2991 holding.
  • Vanguard Capital Management first reported a position in Outlook Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 64 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.